Vanadium: A Panacea for Resistance to Oncolytic Immunotherapy?

Slides:

Advertisements

Similar presentations

Gene Preference in Maple Syrup Urine Disease Mary M. Nellis, Dean J. Danner The American Journal of Human Genetics Volume 68, Issue 1, Pages (January.

Advertisements

209. Use of Helicobacter pyroli Neutrophil Activating Protein (NAP) as an Immune- Modulatory Agent To Enhance the Efficacy of Oncolytic Adenovirus Therapy.

Man's Best Friend: Utilizing Naturally Occurring Tumors in Dogs to Improve Chimeric Antigen Receptor T-cell Therapy for Human Cancers Melinda Mata, Stephen.

Engineering Natural Killer Cells for Cancer Immunotherapy

Converting Cold into Hot Tumors by Combining Immunotherapies

Bridget A. Robinson, Timothy J. Nice Immunity

Genome-editing Technologies for Gene and Cell Therapy

627. Non-Invasive, Multimodal Imaging of Microvesicles with Metabolically Biotinylated, Membrane-Bound Gaussia Luciferase Molecular Therapy Volume.

Engineering T Cells to Functionally Cure HIV-1 Infection

162. Stability of Polymer/Plasmid DNA Complexes In Vitro and In Vivo

281. Rapid Generation of Induced Pluripotent Stem Cells (iPSCs) from the Urine of a Patient with Duchenne Muscular Dystrophy Molecular Therapy Volume.

Sterol-izing Innate Immunity

Volume 13, Issue 1, Pages (January 2006)

Molecular Therapy Volume 20, Pages S261-S262 (May 2012) DOI: /S (16)

Vesicles Spread Susceptibility to Phages

Evolving Gene Therapy in Primary Immunodeficiency

In Vivo Gene Delivery by Nonviral Vectors: Overcoming Hurdles?

Simon Haas, Andreas Trumpp Developmental Cell

Engineering Natural Killer Cells for Cancer Immunotherapy

Volume 26, Issue 2, Pages (February 2018)

Volume 25, Issue 1, Pages 5-7 (January 2017)

Xiuyan Wang, Isabelle Rivière Molecular Therapy - Oncolytics

Volume 152, Issue 1, (January 2013)

724. Blood-Derived Endothelial Progenitor Cells Can Be Isolated With a Novel Method of Diluted Whole Blood Incubation with AMD3100-Induced Mobilization.

Genome-editing Technologies for Gene and Cell Therapy

Valder R Arruda, Patricia Favaro, Jonathan D Finn Molecular Therapy

Premal Lulla, Carlos A. Ramos Molecular Therapy

Volume 22, Issue 1, Pages (January 2014)

71. Boosting the Immunogenicity of an Oncolytic Vaccinia Virus By Expression of DAI Can Enhance Anti-Tumor Immunity in Humanized Mice Mari Hirvinen,

Molecular Therapy Volume 20, (May 2012) DOI: /S (16)

Molecular Therapy Volume 7, Issue 5, (May 2003) DOI: /S (16)

847. Eradication of Therapy-Resistant Human Prostate Tumors Using an Ultrasound Guided Site-Specific Cancer Terminator Virus Delivery Approach Molecular.

Designer Lipids Advance Systemic siRNA Delivery

HIV-1 Vif: Counteracting Innate Antiretroviral Defenses

133. Survival with Normal Neurological Development of the Juvenile Lethal Urea Cycle Defect Arginase Deficient Mouse with AAV Gene Therapy Molecular.

Erratum The American Journal of Human Genetics

660. Bowel/Bladder Sensation and Control in Patients with Spinal Cord Injury Treated with Human Embryonic Stem Cell Therapy Geeta Shroff Molecular Therapy

Oncolytic Virotherapy and Immunogenic Cancer Cell Death: Sharpening the Sword for Improved Cancer Treatment Strategies Samuel T Workenhe, Karen L Mossman

In utero stem cell transplantation and gene therapy: rationale, history, and recent advances toward clinical application Graça Almeida-Porada, Anthony.

Volume 26, Issue 2, Pages (February 2018)

521. Multiplex Genome Editing of TCR°/CD52 Genes as a Platform for “Off the Shelf” Adoptive T-Cell Immunotherapies Molecular Therapy Volume 22, Pages.

IL-1 Can Act as Number One

405. Hindlimb and Forelimb Strength Assessment in a Canine Model of X-Linked Myotubular Myopathy Following AAV-Mediated Gene Replacement Molecular.

Live and Let Die: A New Suicide Gene Therapy Moves to the Clinic

Volume 26, Issue 4, Pages (April 2018)

Volume 25, Issue 1, Pages (January 2017)

674. Molecular, Biochemical and Biomechanical Analysis of Articular Cartilage Repaired with Genetically Modified Chondrocytes Expressing Insulin-Like.

Chimeric antigen receptor T-cell therapy for solid tumors

The Effect of Size and Shape of RNA Nanoparticles on Biodistribution

287. Improved Outcomes Following Drug-Resistant Immunotherapy in a Human Xenograft Model of Temozolomide-Resistant Glioblastoma Multiforme Harold T.

Molecular Therapy Volume 18, Pages S260-S261 (May 2010) DOI: /S (16)

Elizabeth M Hadac, Elizabeth J Kelly, Stephen J Russell

In This Issue Molecular Therapy Volume 16, Issue 4, (April 2008)

Thunder and Lightning: Immunotherapy and Oncolytic Viruses Collide

372. Targeted Mutagenesis of Ubiquitin-Binding Lysine Residues on the Adeno- Associated Virus (AAV)2 Capsid Improves Its Transduction Efficiency Molecular.

Oncolytic Virotherapy and Immunogenic Cancer Cell Death: Sharpening the Sword for Improved Cancer Treatment Strategies Samuel T Workenhe, Karen L Mossman

521. AAV Immunotherapy Induces Functional Antigen Specific Regulatory T-Cells to a Neuroantigen: A Potential Treatment for MS Brad E. Hoffman Molecular.

Oncolytic Virotherapy: A Contest between Apples and Oranges

773. Detection of RNA Interference (RNAi) Mediated mRNA Cleavage in Fresh Injected Tumor Tissue from Patients in a Phase I Trial of pbi-shRNA™ Lipoplex.

740. Prevention of Radiation-Induced Lung Injury by Administration of Gene-Modified Mesenchymal Stem Cells Molecular Therapy Volume 20, Pages S285-S286.

Molecular Therapy Volume 21, Pages S247-S248 (May 2013)

Shigeki Yagyu, Malcolm K. Brenner

History of Oncolytic Viruses: Genesis to Genetic Engineering

86. A Highly Compact Epitope-Based Marker Suicide Gene for Safer and Easier Adoptive T-Cell Gene Therapy Molecular Therapy Volume 20, Pages S35-S36.

Volume 26, Issue 5, Pages (May 2018)

Volume 20, Issue 4, Pages (April 2012)

Sensing Bad: Are Co-stimulatory CAR-Expressing γδ T Cells Safer?

Shirley Wong, Roderick A. Slavcev

Volume 148, Issue 1, (January 2012)

624. Randomized Phase II Trial of Adjuvant Autologous Tumor Cell Vaccine (FANG™) for High Risk Stage III/IV Ovarian Cancer: Preliminary Results Molecular.

Presentation transcript:

Vanadium: A Panacea for Resistance to Oncolytic Immunotherapy? Dmitriy Zamarin Molecular Therapy Volume 26, Issue 1, Pages 9-12 (January 2018) DOI: 10.1016/j.ymthe.2017.12.006 Copyright © 2017 The American Society of Gene and Cell Therapy Terms and Conditions

Figure 1 Pleiotropic Effects of Vanadium Compounds on Oncolytic Immunotherapy (A) Infection with an RNA oncolytic virus leads to virus replication with resultant production of type I IFN, which acts in an autocrine and paracrine fashion to limit viral replication and spread. This leads to limited viral replication, direct tumor cell lysis, and T cell-mediated immunity in vivo. (B) Vanadium compounds in the setting of infection with an RNA oncolytic virus re-wire intracellular signaling in response to type I IFN to induce transcriptional activation consistent with type II IFN response and result in increased virus replication, tumor cell lysis, and T cell recruitment to tumors. Molecular Therapy 2018 26, 9-12DOI: (10.1016/j.ymthe.2017.12.006) Copyright © 2017 The American Society of Gene and Cell Therapy Terms and Conditions